Skip Nav Destination
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS|
November 21, 2024
Ven-Aza outcomes in AML by genetic risk
CME
Blood (2024) 144 (21): 2271.
Connected Content
A related article has been published:
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Citation
Ven-Aza outcomes in AML by genetic risk. Blood 2024; 144 (21): 2271. doi: https://doi.org/10.1182/blood.2024027149
Download citation file:
November 21 2024
Advertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal